Neovalen (Benzylpenicillin Sodium)

Benzylpenicillin Sodium, the active ingredient in Neovalen, is a beta‑lactam antibiotic presented as a sterile injectable for intramuscular and intravenous use. It treats a range of bacterial infections, including streptococcal disease, meningitis, syphilis, and pneumonia, in adult and pediatric patients.

GNH USA supplies Neovalen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for importers. Its global logistics network ensures timely delivery across multiple continents.

Neovalen (benzylpenicillin sodium) is employed to treat bacterial infections by targeting the cell wall synthesis pathway.

- Streptococcal infections: eradicates the causative streptococci and resolves throat and skin manifestations. - Meningitis: provides rapid bactericidal activity to clear meningococcal or pneumococcal pathogens in the cerebrospinal fluid. - Syphilis: eliminates Treponema pallidum during early and late stages of disease. - Pneumonia: treats community‑acquired bacterial pneumonia caused by susceptible organisms. - Severe bacterial infections: offers broad‑spectrum coverage for systemic infections requiring parenteral therapy.

Adverse reactions to Neovalen are generally related to its penicillin nature and route of administration.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the intramuscular or intravenous site. - Transient fever or chills: short‑lasting pyrexia after dosing. - Nausea or vomiting: gastrointestinal upset following administration. - Rash or urticaria: mild skin eruption.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction requiring immediate medical attention. - Serum sickness‑like reaction: fever, arthralgia, and rash occurring days to weeks after exposure. - Clostridioides difficile colitis: severe diarrhea due to disruption of normal gut flora. - Hemolytic anemia: immune‑mediated destruction of red blood cells, rare but serious.

Before prescribing Neovalen, clinicians should evaluate several safety considerations. - Allergy assessment: confirm no history of hypersensitivity to penicillins or β‑lactam antibiotics. - Renal function: adjust dosing in patients with impaired kidney clearance. - Concurrent bacteriostatic agents: avoid use with tetracyclines or chloramphenicol as they may antagonize bactericidal activity. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Superinfection risk: monitor for secondary infections such as candidiasis or C. difficile. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Neovalen may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Bacteriostatic antibiotics (e.g., tetracycline, chloramphenicol, macrolides): may reduce penicillin’s bactericidal effect. - Anticoagulants (e.g., warfarin): potentiates anticoagulant effect, increasing bleeding risk. - Methotrexate: concurrent use can enhance methotrexate toxicity.

Moderate Interactions (Monitor Closely): - Probenecid: decreases renal excretion, raising penicillin plasma levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of renal impairment. - Oral contraceptives: may slightly reduce hormonal efficacy, advise additional contraceptive measures.